Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban Biomarker Study in CAD and PAD
NCT04059679Phase 4Unknown
- Sponsor
- LifeBridge Health
- Start
- Jan 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rivaroxaban in coronary artery disease (CAD), peripheral artery disease (PAD), sponsored by LifeBridge Health. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
coronary artery disease (CAD)peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT04059679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04059679.